(Q39377591)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

main subject

phase II clinical trial

0 references

0 references

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

David Paling

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

Claudia Wheeler-Kingshott

6 March 2020

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

17

David H Miller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Rhian Raftopoulos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Simon J Hickman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Basil Sharrack

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Shahrukh Mallik

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Daniel R Altmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Marios C Yiannakas

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Prasad Malladi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Rose Sheridan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Ptolemaios G Sarrigiannis

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Nigel Hoggard

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Martin Koltzenburg

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Klaus Schmierer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Raju Kapoor

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Gavin Giovannoni

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

26 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

259-269

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

Axonal pathology in multiple sclerosis: relationship to neurologic disability

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Phenytoin: mechanisms of its anticonvulsant action

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Visual recovery following acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Vision and vision-related outcome measures in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Oral versus intravenous steroids for treatment of relapses in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

MRI acquisition and analysis protocol for in vivo intraorbital optic nerve segmentation at 3T.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Quantifying axonal loss after optic neuritis with optical coherence tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Corticosteroids do not prevent optic nerve atrophy following optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Memantine for axonal loss of optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Sodium channel expression within chronic multiple sclerosis plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900004-1

7 January 2021

10.1016/S1474-4422(16)00004-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822749%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference